REDWOOD CITY, Calif., Oct. 3 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), will host a conference call today at 4:30 p.m. ET to discuss the Phase 2 and Phase 3 presentations that were made at the ECCO proceedings last week.
Joining the Company on the conference call will be Dr. Gabi Chiorean, Assistant Professor of Medicine from the Indiana University Cancer Center in Indianapolis, Indiana. Dr. Chiorean is the principle investigator on Threshold's Phase 2 glufosfamide trial in first-line pancreatic cancer patients, and she was present at ECCO to preside over the Phase 2 poster. Also on the conference call will be Dr. Virginia Langmuir who was the medical monitor for both the Phase 2 and the Phase 3 glufosfamide studies.
To access the live teleconference, dial 888-401-4690. To access the live audio webcast or the subsequent archived recording please log on to the Investor section of the Threshold Pharmaceuticals, Inc. website: http://www.thresholdpharm.com.
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer. By selectively targeting abnormally-proliferating tumor cells, the Company's drug candidates are designed to be potentially more effective and less toxic to healthy tissues than conventional treatments. For additional information, please visit our website (http://www.thresholdpharm.com).
Denise T. Powell
Sr. Director, Corporate Communications
Threshold Pharmaceuticals, Inc.
|SOURCE Threshold Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved